Special access scheme will accelerate the plan to supply medicinal cannabis products.
() has achieved a major breakthrough following the establishment of a special access scheme which enables access for Chilean patients to medicinal cannabis products.
AusCann’s joint venture partner, Fundación Daya has worked with the Chilean National Institute of Public Health to establish the special access scheme.
READ: AusCann Group's vertically integrated model provides point of difference in medicinal cannabis industry
A similar access scheme is used in Australia, which enables doctors to prescribe cannabinoid medicines prior to product registration.
Second cannabis crop is getting ready for harvest
AusCann and Fundación Daya’s joint venture, DayaCann, is the only company in Chile to hold a medical cannabis production licence.
DayaCann has a proven growing record with the first crop yielding over 400 kilograms of dried cannabis in 2017.
The second crop has been planted and is scheduled for harvest this year.
Aiming to supply medicinal cannabis products for the treatment of pain
AusCann managing director Elaine Darby said: “We are delighted with the establishment of this special access scheme.
“DayaCann’s second crop is almost ready for harvest, and this special access scheme will accelerate the joint venture’s goal of producing and supplying final dose form medicines for the treatment of pain in the Latin American market”
READ: AusCann Group to collaborate in enhancing medicinal cannabis production
The new special access scheme (SAS) will be applied to a medical cannabis product being locally produced at Knop Laboratories from cannabis supplied by DayaCann.
The SAS allows patients to access the products whilst clinical trials for product registration are being completed.
The patients can apply to their doctors for a prescription, which will be approved by the public health department on a case-by-case basis.
Phase II pain management trial progressing in cancer patients
Phase I trials have been completed, and a phase II trial is being conducted for pain management in cancer patients at a Chilean public health centre.
The cannabinoid medicines being supplied under the SAS will be mainly accessed by patients of 15 municipalities who participated in the funding of earlier plantings by Fundación Daya.
As a result of this participation, a specified number of residents will receive free access to a year’s treatment.
Patients outside of these municipalities will be able to buy the products in pharmacies with their official permit approved by the Chilean National Institute of Public Health.
